The uterotonic ergot alkaloids — ergometrine (ergonovine in North American nomenclature) and its semisynthetic derivative methylergonovine (methylergonovine maleate, Methergine) — produce powerful, sustained uterine contractions through a multireceptor mechanism that is mechanistically distinct from oxytocin. Their receptor pharmacology explains both their exceptional efficacy in the contracted, estrogen-primed postpartum uterus and the systemic cardiovascular toxicity that emerges when the same receptor systems are activated in non-uterine vascular smooth muscle.
The myometrium expresses a rich complement of contractile receptors, and the uterotonic ergot alkaloids activate at least three of them simultaneously. Alpha-1 adrenergic receptors (alpha-1 ARs) are expressed on myometrial smooth muscle cells and mediate contraction through Gq coupling, phospholipase C (PLC) activation, inositol trisphosphate (IP3)-mediated calcium release from the sarcoplasmic reticulum, and diacylglycerol (DAG)-mediated protein kinase C (PKC) activation. Methylergonovine is a partial agonist at alpha-1 ARs, producing submaximal receptor activation at the myometrium but sufficient to contribute materially to uterine smooth muscle tone. The serotonin 5-HT2A receptor is a second major effector in uterotonic ergot action; 5-HT2A receptors on myometrial smooth muscle are also Gq-coupled and mediate the same intracellular calcium mobilization pathway as alpha-1 ARs. Methylergonovine and ergometrine are partial agonists at 5-HT2A receptors in uterine smooth muscle, contributing to the sustained tonic contraction that is the hallmark of ergot uterotonic action. The relative contributions of alpha-1 AR and 5-HT2A receptor agonism to the overall uterotonic effect differ between ergometrine and methylergonovine due to their slightly different receptor affinity profiles, but both pathways are active with each agent.1
Oxytocin receptors are a third target, and their role in ergot uterotonic action is indirect but clinically significant. Methylergonovine and ergometrine do not bind meaningfully to oxytocin receptors; their interaction with this system is instead through modulation of oxytocin receptor signaling in the postpartum myometrium. The sustained calcium mobilization produced by alpha-1 AR and 5-HT2A agonism sensitizes myometrial oxytocin receptors, making the contracted postpartum uterus more responsive to the endogenous oxytocin surge that accompanies delivery of the placenta and breastfeeding. This receptor cross-sensitization contributes to the synergistic uterotonic effect observed when methylergonovine and oxytocin are combined in postpartum hemorrhage (PPH) treatment protocols, where the ergot provides sustained tonic contraction while oxytocin maintains rhythmic contractile activity.3
The physiological state of the myometrium at the time of ergot alkaloid administration determines the magnitude and quality of the uterotonic response. Estrogen priming of the myometrium during pregnancy progressively upregulates alpha-1 AR density and 5-HT2A receptor expression in uterine smooth muscle, producing a state of high receptor density and high contractile sensitivity in the term myometrium that is not present in the non-pregnant state. This explains why methylergonovine and ergometrine produce powerful uterotonic responses in the postpartum uterus at doses that would produce negligible uterine effects in a non-pregnant woman. Progesterone, which dominates in early and mid-pregnancy, has the opposite effect: it reduces myometrial receptor sensitivity and maintains uterine quiescence. The dramatic decline in progesterone and surge in estrogen that characterize the peripartum period prime the myometrium to respond maximally to ergot uterotonic agents.2
Oxytocin produces rhythmic, phasic contractions mimicking physiological labor contractions, with relaxation intervals between contractions that maintain uteroplacental blood flow. Methylergonovine and ergometrine produce sustained tonic contractions with minimal or no relaxation phases, maintaining a persistently elevated myometrial tone. This tonic contraction pattern achieves hemostasis at the placental bed by mechanically compressing the uterine sinusoids — the spiral arteries that supplied the intervillous space — from the inside, reducing blood loss from the open placental implantation site. The tonic pattern is superior for hemostasis but means that ergot agents cannot be safely used to augment or induce labor, where sustained tonic uterine contraction would compromise uteroplacental blood flow and cause fetal hypoxia.
The vascular smooth muscle effects of uterotonic ergot alkaloids arise from the same alpha-1 AR and 5-HT2A receptor agonism that produces uterotonic activity. All vascular smooth muscle expresses alpha-1 ARs, and arterial smooth muscle in peripheral and coronary vessels responds to methylergonovine and ergometrine with vasoconstriction through the same Gq-mediated calcium mobilization mechanism as the myometrium. The 5-HT2A receptor is also expressed in vascular smooth muscle and contributes to vasoconstriction. At the doses used for PPH prevention and treatment, these systemic vascular effects produce modest increases in blood pressure in most patients, but in patients with pre-existing hypertension, pre-eclampsia, or coronary artery disease, the vasoconstrictive response can be severe enough to cause hypertensive emergency or coronary arterial vasospasm. The postpartum period is physiologically a high cardiac output, low peripheral resistance state; superimposing ergot-mediated vasoconstriction on this hemodynamic context is the pharmacological explanation for the cardiovascular complications that define the primary risk of uterotonic ergot use.1
Methylergonovine maleate is the preferred uterotonic ergot alkaloid in current obstetric practice in most settings where it is used, having largely replaced ergometrine because of its more favorable vascular versus uterine selectivity profile and its more predictable pharmacokinetic behavior. Its ADME profile, particularly the striking pharmacokinetic differences between intramuscular and intravenous administration, has important implications for how the drug should be used clinically and why certain routes carry substantially higher cardiovascular risk.
Absorption of methylergonovine after intramuscular (IM) injection is rapid, with onset of uterine contraction within 2–5 minutes and peak plasma concentrations (Cmax) achieved within 20–30 minutes. The absorption rate from the IM site is governed by local blood flow, which in the well-perfused postpartum state is adequate to produce consistently rapid uptake. Oral bioavailability of methylergonovine is approximately 60%, substantially higher than ergotamine or ergometrine, because methylergonovine has lower lipophilicity and less susceptibility to intestinal CYP3A4 metabolism than the more complex ergopeptine alkaloids. Oral Cmax is reached within 0.5–2 hours after ingestion, with onset of uterotonic effect within 5–10 minutes for sublingual administration. The oral route is used for the extended postpartum course (typically 0.2 mg three to four times daily for 2–7 days after delivery) to maintain uterine tone during the period of maximal PPH risk.1
Distribution of methylergonovine is extensive, with a volume of distribution (Vd) of approximately 39–73 liters per kilogram, reflecting high tissue affinity driven by the drug's moderate lipophilicity and extensive tissue binding. Plasma protein binding is approximately 36%, substantially lower than ergotamine (approximately 93%) or cabergoline (40–42%), and the large Vd means that plasma concentrations decline rapidly as drug distributes into peripheral tissues, even while pharmacodynamically effective concentrations persist at the myometrium. This distribution pattern contributes to the apparent disconnect between the short plasma half-life and the prolonged uterotonic effect: plasma concentrations can be undetectable while uterine tone remains elevated due to drug retained in myometrial tissue. Methylergonovine crosses the placenta and is detectable in cord blood at delivery when administered before delivery, and is secreted into breast milk at low concentrations; neonatal exposure from breast milk during postpartum treatment is generally considered low but should be considered in preterm infants.3
Metabolism of methylergonovine occurs primarily in the liver through cytochrome P450 3A4 (CYP3A4)-mediated hydroxylation and through non-enzymatic hydrolysis of the lysergic acid amide bond. The CYP3A4 dependence is less pronounced than for ergotamine because methylergonovine's smaller molecular structure offers fewer sites for CYP3A4 oxidation. The primary metabolite is lysergol, which retains modest pharmacological activity. The elimination half-life of methylergonovine is approximately 2–3.5 hours, supporting the three to four times daily dosing interval for the oral postpartum course. Excretion is predominantly biliary and fecal, with a smaller renal component; hepatic impairment reduces clearance and may prolong the elimination phase significantly, warranting dose reduction or alternative agent selection in patients with significant liver dysfunction. Total body clearance is approximately 14–16 liters per hour, consistent with moderately high hepatic extraction. Renal impairment does not substantially alter methylergonovine elimination and does not require routine dose adjustment.1
Intravenous administration of methylergonovine achieves immediate peak plasma concentrations, bypassing the absorption phase and delivering the full dose directly to the systemic circulation. This produces a rapid, intense peripheral vasoconstrictive response before uterine distribution can occur, dramatically amplifying the cardiovascular risk relative to the IM route. Severe acute hypertension, coronary artery vasospasm, stroke, and death have been reported after IV methylergonovine administration, predominantly in women with pre-existing or unrecognized hypertension, pre-eclampsia, or cocaine use (which already produces alpha-1 AR and serotonin receptor hypersensitivity). Current guidelines from the American College of Obstetricians and Gynecologists (ACOG) specify that IV methylergonovine should be administered only for life-threatening hemorrhage, diluted and given over at least one minute while monitoring blood pressure continuously, and never as a rapid IV bolus. The IM route (0.2 mg) provides equivalent uterotonic efficacy with a substantially safer cardiovascular profile for routine active management of the third stage of labor.
The pharmacokinetic profile of methylergonovine following IV administration differs substantially from the IM route in clinically important ways beyond the cardiovascular risk difference. After IV dosing, uterine contraction onset is within 45–60 seconds (compared with 2–5 minutes for IM), but the duration of effective uterotonic action is approximately 45 minutes (compared with 1–3 hours for IM). This shorter duration reflects the rapid distribution from plasma to tissues after IV peak, followed by redistribution away from the myometrium as equilibration occurs across a large Vd. For sustained PPH control in the emergency setting, the IV route therefore typically requires repeat dosing or transition to an IM maintenance regimen, making the combination of IV for immediate effect and IM for duration the standard approach in high-volume obstetric hemorrhage management when IV access is established and cardiovascular risk has been excluded.3
Postpartum hemorrhage (PPH) is defined as blood loss exceeding 500 mL within 24 hours of vaginal delivery or exceeding 1,000 mL following cesarean delivery, and it remains the leading cause of maternal mortality worldwide, accounting for approximately 27% of maternal deaths globally. Active management of the third stage of labor (AMTSL) — the period from delivery of the infant to delivery of the placenta — with prophylactic uterotonics is the single most effective intervention for PPH prevention, reducing PPH incidence by approximately 60% compared with expectant management.
Active management of the third stage of labor combines prophylactic uterotonic administration, controlled cord traction to facilitate placental delivery, and uterine massage after placental delivery. The uterotonic component is the most pharmacologically important element. The World Health Organization (WHO) recommends oxytocin (10 IU intramuscularly) as the preferred first-line uterotonic for AMTSL in all settings, based on evidence that oxytocin reduces PPH risk without the cardiovascular risks associated with ergot alkaloids. When oxytocin is unavailable, the WHO lists ergometrine or the fixed combination of oxytocin plus ergometrine (Syntometrine: 5 IU oxytocin + 0.5 mg ergometrine, given IM) as acceptable alternatives. The combination has been shown in randomized trials to reduce the risk of PPH and the need for additional uterotonics compared with oxytocin alone, but at the cost of increased rates of nausea, vomiting, and hypertension — reflecting the ergometrine component.4
Methylergonovine 0.2 mg IM is the ACOG-recommended ergot uterotonic for AMTSL in settings where oxytocin alone is insufficient. The ACOG guidelines specify that methylergonovine should not be used in women with hypertension, pre-eclampsia, or hemodynamic instability from any cause, as the vasoconstrictive effect of methylergonovine in the context of already-elevated systemic vascular resistance risks precipitating hypertensive crisis, myocardial ischemia, or stroke. In low-resource settings where refrigeration of oxytocin is not reliably available, heat-stable misoprostol (a prostaglandin E1 analog) has replaced ergometrine as the preferred AMTSL uterotonic, given its oral route of administration, heat stability, and lack of cardiovascular contraindications, though its uterotonic efficacy is modestly inferior to parenteral oxytocin or ergot combinations in high-resource settings.5
When PPH occurs despite prophylactic uterotonic administration, treatment follows a stepwise uterotonic escalation protocol. First-line treatment for uterine atony (the most common cause of PPH, responsible for approximately 80% of cases) is oxytocin 20–40 IU in 1 liter of normal saline infused at 500 mL per hour, combined with bimanual uterine massage and bladder drainage. When oxytocin infusion fails to achieve adequate uterine tone, methylergonovine 0.2 mg IM (or IV if hemorrhage is life-threatening and blood pressure allows) is added as second-line uterotonic. The combination of oxytocin and methylergonovine is synergistic: oxytocin maintains rhythmic phasic contractions and uterotonic receptor stimulation, while methylergonovine superimposes sustained tonic contraction through the alpha-1 AR and 5-HT2A pathway. If this combination fails, prostaglandin F2-alpha (carboprost tromethamine, Hemabate, 250 micrograms IM every 15–90 minutes, maximum 8 doses) or misoprostol 800–1,000 micrograms rectally are used as third-line agents.3
The four Ts of PPH etiology — Tone (uterine atony, 80%), Trauma (lacerations, uterine rupture), Tissue (retained placenta or membranes), and Thrombin (coagulopathy) — determine which interventions are appropriate. Uterotonic agents including methylergonovine and oxytocin are effective only for Tone (atony); they have no role in PPH due to trauma, retained tissue, or coagulopathy, and delay of surgical or manual interventions by continued uterotonic escalation in these settings can be fatal. Rapid identification of the etiology of PPH — by uterine examination, inspection of birth canal, and assessment of coagulation — is the essential clinical step that determines whether uterotonic escalation or a different intervention is needed.
The duration of oral methylergonovine therapy after delivery is a clinical decision that balances the ongoing risk of delayed PPH (which peaks in the first 24 hours but can occur up to 12 weeks postpartum in the case of secondary PPH from subinvolution of the placental bed or retained placental fragments) against the cumulative cardiovascular risk of continued vasoconstriction. Standard practice in most obstetric units is to continue oral methylergonovine 0.2 mg three to four times daily for 2–7 days following delivery for patients who required uterotonic treatment beyond the immediate third stage, or for patients at high risk for subinvolution (uterine fibroids, multiparity, prolonged labor, oxytocin augmentation). The decision to extend methylergonovine beyond 7 days should be based on clinical assessment of uterine involution, and blood pressure should be monitored at each dose escalation and during the initial days of oral treatment.6
The cardiovascular contraindications to methylergonovine and ergometrine are not merely theoretical. The drugs reliably produce systemic vasoconstriction at doses required for uterotonic efficacy, and in patients with predisposing conditions, this vasoconstriction has caused fatal outcomes including acute myocardial infarction, stroke, and hypertensive encephalopathy. The contraindication profile must be assessed before every administration, including in emergency settings, because many of the predisposing conditions are present in exactly the patients who are at highest risk of PPH.
Hypertension and pre-eclampsia represent the most critical contraindications and the most common clinical scenario where ergot uterotonics are inappropriately administered. Pre-eclampsia, which is defined by new-onset hypertension (blood pressure greater than or equal to 140/90 mmHg) with proteinuria or end-organ dysfunction at or after 20 weeks of gestation, is associated with diffuse endothelial dysfunction, arteriolar vasospasm, and markedly increased vascular responsiveness to vasoconstrictor stimuli. Methylergonovine administration in a pre-eclamptic patient superimposes pharmacological vasoconstrictive drive on a vasculature that is already operating near its pressure limits, and the combined effect reliably causes acute severe hypertension. Systolic blood pressure elevations of 40–60 mmHg within 5–15 minutes of IM methylergonovine have been documented in pre-eclamptic patients in case series, with associated complications including posterior reversible encephalopathy syndrome (PRES), intracerebral hemorrhage, and acute coronary syndrome. The contraindication is absolute: no uterotonic indication justifies ergot use in pre-eclampsia; oxytocin, misoprostol, or carboprost are the appropriate alternatives.7
Coronary artery disease and coronary artery vasospasm (Prinzmetal angina) are absolute contraindications because the vasoconstrictive effect of methylergonovine is not selective for the uterine vasculature and extends to the coronary arteries. Multiple case reports of acute myocardial infarction (MI) following methylergonovine administration exist, predominantly in women with unrecognized coronary artery disease, cocaine use (which sensitizes coronary arteries to vasoconstrictive stimuli), or ergotamine use for migraine (which suggests pre-existing coronary vasoreactivity). The postpartum period itself carries an increased risk of acute MI independent of drug use, related to the hemodynamic stress of labor and the thrombogenic postpartum state, and ergot uterotonics in patients with predisposing coronary risk factors amplify this already-elevated risk. Any patient with a history of MI, coronary revascularization, or angina should receive oxytocin alone for uterotonic management, regardless of hemorrhage severity, and carboprost or misoprostol should be available as alternatives if oxytocin monotherapy fails.3
Acute severe hypertension following methylergonovine requires immediate assessment and management. First, place the patient in left lateral decubitus to relieve aortocaval compression and optimize venous return. If systolic blood pressure exceeds 160 mmHg or diastolic exceeds 110 mmHg (the thresholds defining acute severe hypertension in obstetrics), pharmacological treatment is required within 30–60 minutes. Agents: labetalol IV (20 mg initial, then 40–80 mg every 10 minutes, maximum 300 mg), hydralazine IV (5–10 mg every 20 minutes), or nifedipine oral immediate-release (10 mg, repeat in 30 minutes if needed). Nitroprusside IV is reserved for refractory cases (risk of fetal cyanide toxicity in the antepartum context, though for postpartum use this is less restrictive). Methylergonovine should not be re-administered. Document the event, blood pressure readings, and all interventions in the medical record, as methylergonovine-induced hypertensive emergency constitutes a serious adverse event requiring review.
Drug interactions relevant to methylergonovine in the obstetric setting include two categories of particular clinical importance. The first is the interaction with vasopressors and vasoconstrictors used in obstetric anesthesia. Phenylephrine and ephedrine, used to treat spinal anesthesia-induced hypotension during cesarean delivery, are vasoconstrictors that act additively with methylergonovine if both are administered within the same perioperative window. Ergot-induced alpha-1 AR activation combined with phenylephrine's pure alpha-1 AR agonism can produce additive or synergistic hypertension, particularly in women who receive a spinal anesthetic (which itself causes hypotension, often treated with phenylephrine), then receive methylergonovine for PPH — the blood pressure trajectory can reverse dramatically from hypotension to hypertension within minutes. Communication between the obstetrician and anesthesiologist about uterotonic selection at the time of delivery is an important perioperative safety practice. The second interaction class is CYP3A4 inhibitors: macrolide antibiotics (erythromycin, clarithromycin), azole antifungals, and HIV protease inhibitors can increase methylergonovine plasma concentrations, potentially prolonging and intensifying both uterotonic and vasoconstrictive effects, though this interaction is less acutely severe with methylergonovine than with ergotamine.1
Ergometrine (ergonovine maleate) is the parent compound of methylergonovine and the original clinical uterotonic ergot alkaloid, introduced into obstetric practice in the 1930s. The two compounds share the same basic pharmacological mechanism but differ in receptor affinity profiles, ADME characteristics, and adverse effect profiles in ways that have progressively made methylergonovine the preferred ergot option where ergot uterotonics are used, and misoprostol or oxytocin the preferred first-line agents where ergot risks are deemed unacceptable.
Ergometrine (ergonovine maleate) is the simplest of the clinically used ergot alkaloids in terms of molecular structure, being the amide of lysergic acid with the amino alcohol ethanolamine rather than a tripeptide substituent. Its molecular simplicity relative to ergotamine and methylergonovine is reflected in its slightly more favorable systemic vasoconstriction profile at the doses used clinically for PPH prevention, but this difference is pharmacologically modest, and the same cardiovascular contraindications that apply to methylergonovine apply fully to ergometrine. Ergometrine has substantially higher emetic activity than methylergonovine due to greater dopamine D2 receptor activity at the chemoreceptor trigger zone; this emetic potency is the primary reason for the prominent nausea and vomiting that accompany Syntometrine (ergometrine plus oxytocin), particularly when administered IM — the ergometrine-induced chemoreceptor trigger zone (CTZ) activation produces vomiting in 20–40% of patients, compared with less than 10% with oxytocin alone. Ergometrine is more heat-labile than methylergonovine and requires refrigerated storage at 2–8 degrees Celsius, which is a practical limitation in low-resource settings where temperature-controlled cold chain supply chains are unreliable.4
Absorption of ergometrine after IM injection is rapid, with onset of uterine contraction within 2–3 minutes and peak effect at 5–10 minutes, slightly faster than methylergonovine. Oral bioavailability is approximately 25–47%, lower than methylergonovine's approximately 60%, reflecting greater first-pass hepatic metabolism. The elimination half-life of ergometrine is approximately 2 hours, slightly shorter than methylergonovine's 2–3.5 hours, requiring more frequent dosing for an extended oral postpartum course. Sublingual ergometrine achieves faster onset than oral administration and avoids first-pass metabolism, with bioavailability similar to IM in some studies, representing an option when injection is not feasible. Distribution is extensive, with substantial tissue binding; protein binding is approximately 50%. CYP3A4 mediates the primary metabolic pathway. Excretion is predominantly biliary-fecal. In practice, the ADME differences between ergometrine and methylergonovine are clinically secondary to their pharmacodynamic similarities; the choice between agents is driven more by local formulary availability, storage requirements, and emetic side effect profiles than by pharmacokinetic considerations.8
Oxytocin (10 IU IM or 20–40 IU in 1 L IV infusion): First-line for AMTSL and atony treatment; phasic contractions; no cardiovascular contraindications; requires refrigeration; tachyphylaxis with prolonged infusion. Methylergonovine (0.2 mg IM): Sustained tonic contraction; no oxytocin receptor; absolute contraindication in hypertension and pre-eclampsia; avoid IV bolus; 2–3.5 h half-life. Ergometrine (0.5 mg IM): Slightly faster onset; higher emetic activity; same cardiovascular contraindications as methylergonovine; heat-labile. Carboprost (PGF2-alpha, 250 micrograms IM): Third-line; absolute contraindication in asthma (bronchospasm); relative contraindication in hypertension; significant diarrhea, vomiting; maximum 8 doses. Misoprostol (PGE1, 600–1,000 micrograms oral/sublingual/rectal): Heat-stable; no cardiovascular contraindication; no injection; inferior efficacy to oxytocin in high-resource settings; shivering, fever common.
The role of ergot alkaloids in contemporary obstetric practice has narrowed substantially over the past three decades as the evidence base for oxytocin and misoprostol has matured. The WHO's current recommendation placing oxytocin as sole first-line uterotonic for AMTSL reflects a considered assessment that the cardiovascular risks of ergot alkaloids — even at the low doses used for PPH prevention — are unacceptable as a routine prophylactic measure in the general obstetric population, given that oxytocin provides equivalent or superior PPH prevention without those risks. Ergot uterotonics retain clinical value in two specific scenarios: as second-line agents for atonic PPH that has not responded to adequate oxytocin therapy, and in combination (Syntometrine) when the primary concern is reducing need for additional uterotonics in a setting where PPH risk is particularly high. In both scenarios, rapid blood pressure assessment before administration is the non-negotiable safety checkpoint. The pharmacology of ergot uterotonics is not obsolete — it is precisely targeted, mechanistically understood, and clinically valuable in the right patient at the right moment — but their routine use has appropriately yielded to agents with safer cardiovascular profiles for prophylactic application.5
Before any methylergonovine or ergometrine dose, confirm all of the following:
Blood pressure measured within the preceding 30 minutes: systolic below 140 mmHg and diastolic below 90 mmHg. No history of hypertension, pre-eclampsia, or gestational hypertension in the current or prior pregnancy. No history of coronary artery disease, MI, peripheral vascular disease, or vasospastic conditions. No cocaine use (sensitizes vascular alpha-1 ARs and serotonin receptors to ergot-induced vasospasm). No concurrent use of potent CYP3A4 inhibitors (macrolides, azoles, HIV protease inhibitors). No concurrent vasopressor administration (phenylephrine, ephedrine) in the preceding 15 minutes. Route confirmed as IM (not IV) unless life-threatening hemorrhage and blood pressure monitoring is continuous. Emergency antihypertensive agents (labetalol IV, hydralazine IV, or nifedipine oral immediate-release) available at bedside before administration in any patient with borderline blood pressure readings.
de Groot AN, van Dongen PW, Vree TB, Hekster YA, van Roosmalen J. Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs. 1998;56(4):523–535.
doi:10.2165/00003495-199856040-00002Fuchs AR, Fuchs F. Endocrinology of human parturition: a review. Br J Obstet Gynaecol. 1984;91(10):948–967.
doi:10.1111/j.1471-0528.1984.tb03671.xAmerican College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 183: postpartum hemorrhage. Obstet Gynecol. 2017;130(4):e168–e186.
doi:10.1097/AOG.0000000000002351Begley CM, Gyte GM, Devane D, McGuire W, Weeks A, Biesty LM. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev. 2019;2(2):CD007412.
doi:10.1002/14651858.CD007412.pub5World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: WHO; 2012.
Anderson JM, Etches D. Prevention and management of postpartum hemorrhage. Am Fam Physician. 2007;75(6):875–882.
Collins PW, Bell SF, de Lloyd L, Collis RE. Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience. Int J Obstet Anesth. 2019;37:106–117.
doi:10.1016/j.ijoa.2018.08.008Moir DD, Amoa AB. Ergometrine or oxytocin? Blood loss and side-effects at spontaneous vertex delivery. Br J Anaesth. 1979;51(2):113–117.
doi:10.1093/bja/51.2.113